Abstract
Resistomycin, a quinone-related natural antibiotic, has shown strong inhibitory activity against human hepatocellular carcinoma (HCC) in vitro. Here, we investigated the role of p38 MAPK in the pro-apoptotic and G2/M phase arrest action of HCC HepG2 cells upon treatment with resistomycin in vitro and in vivo. Our results showed that resistomycin dose- and time-dependently reduced the viability of HepG2 cells and also showed lower cytotoxicity in normal human kidney cells (293T) and hepatocyte cells (HL-7702). Resistomycin treatment induced apoptosis and cell cycle arrest in HepG2 cells, accompanied by changes in the expression of related proteins, including Bax, Cyclin B1, etc. Surprisingly, resistomycin-mediated apoptotic cell death and cell cycle arrest were impeded by SB203580 (an inhibitor of p38 catalytic activity), suggesting that p38 MAPK signaling may play an important role that impedes eventual cell death. In this connection, data in vitro and in vivo demonstrated that resistomycin increased the phosphorylation of p38 and MAPKAPK-2 in HepG2 cells. Furthermore, we provided evidence that p38 signaling is involved in resistomycin-induced p38 MAPK pathway effects in HCC, using computer docking models. Our study indicated that resistomycin activates the p38 MAPK signaling pathway by which the growth of HepG2 cells is suppressed for apoptosis and G2/M phase arrest in vitro and in vivo, and it is a promising therapeutic leading compound for drug development in HCC treatment.
Highlights
According to the latest global cancer burden data from the International Agency for Research on Cancer in 2020, the number of new live cancers increased by about 900,000(4.7%), ranking sixth in new cancer cases, and the more than 800,000 (8.3%) deaths ranked third [1]
Sorafenib was the first drug approved by the Food and Drug Administration (FDA) in 2005 to treat advanced hepatic cancers and, soon afterwards, the China Food and
We report that resistomycin induced apoptosis and G2/M phase arrest of HepG2 cells in vitro and in vivo, with the p38 Mitogen-activated protein kinase (MAPK) signaling pathway being involved in this action
Summary
(4.7%), ranking sixth in new cancer cases, and the more than 800,000 (8.3%) deaths ranked third [1]. The third primary cause of cancer death is liver cancer and hepatocellular carcinoma (HCC) plays a significant role in this [1,2,3]. The main etiological factors of HCC include chronic hepatitis (B or C) virus infection and alcoholic liver disease [4,5]. Sorafenib was the first drug approved by the Food and Drug Administration (FDA) in 2005 to treat advanced hepatic cancers and, soon afterwards, the China Food and. Drug Administration (CFDA) approved use of the drug [7,8]. About 10 years later, regorafenib, the second drug for HCC treatment, was approved by the FDA and CFDA [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
